Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis

References

• Eghbali A, Khalilpour A, Taherahmadi H, et al. Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: a randomized, controlled study. Therapie. 2019;74(5):507–512.
   PubMed Web of Science ®Google Scholar
• Wang Y, Song W. Perioperative application of proton pump inhibitors to prevent stress ulcer. Int J Clin Exp Med. 2016;9(8):16771–16776.
   Google Scholar
• Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–246.
   PubMed Web of Science ®Google Scholar
• Klatte DCF, Gasparini A, Xu H, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2021;153(3):702–710.
   Google Scholar
• Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2020;75(4):497–507.
   PubMed Web of Science ®Google Scholar
• Hung S-C, Liao K-F, Hung H-C, et al. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study. Fam Pract. 2018;35(2):166–171.
   PubMedGoogle Scholar
• Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–1010.
   PubMed Web of Science ®Google Scholar
• Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of clostridium difficile infection. J Hosp Infect. 2018;98(1):4–13.
   PubMed Web of Science ®Google Scholar
• Hess MW, Hoenderop JGJ, Bindels RJM, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405–413.
   PubMed Web of Science ®Google Scholar
• Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–2442.
   PubMed Web of Science ®Google Scholar
• Lam JR, Schneider JL, Quesenberry CP, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821–829.
   PubMed Web of Science ®Google Scholar
• Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552–558.
   PubMed Web of Science ®Google Scholar
• Batchelor R, Gilmartin JF-M, Kemp W, et al. Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review. J Gastroenterol Hepatol. 2017;32(8):1426–1435.
   PubMed Web of Science ®Google Scholar
• Lundell L, Vieth M, Gibson F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–663.
   PubMed Web of Science ®Google Scholar
• Lee JK, Merchant SA, Schneider JL, et al. Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population. Am J Gastroenterol. 2020;115(5):706–715.
   PubMedGoogle Scholar
• Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case–control study. Gastroenterology. 2007;133(4):755–760.
   PubMedGoogle Scholar
• Shin G-Y, Park JM, Hong J, et al. Use of proton pump inhibitors vs histamine 2 receptor antagonists for the risk of gastric cancer: population-based cohort study. Am J Gastroenterol. 2021;116(6):1211–1219.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020;55(4):453–461.
   PubMedGoogle Scholar
• Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019;12:1756284819834511.
   Web of Science ®Google Scholar
• Shao Y-HJ, Chan T-S, Tsai K, et al. Association between proton pump inhibitors and the risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48(4):460–468.
   PubMed Web of Science ®Google Scholar
• Kamal H, Sadr-Azodi O, Engstrand L, et al. Association between proton pump inhibitor use and biliary tract cancer risk: a Swedish population-based cohort study. Hepatology. 2021;74(4):2021–2031.
   PubMedGoogle Scholar
• Xu Q, Jia X, Wu Q, et al. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks. Oncol Lett. 2020;20(6):329.
   PubMedGoogle Scholar
• Kim YS, Lee HJ, Park J-M, et al. Targeted molecular ablation of cancer stem cells for curing gastrointestinal cancers. Expert Rev Gastroenterol Hepatol. 2017;11(11):1059–1070.
   PubMed Web of Science ®Google Scholar
• Fais S. Evidence-based support for the use of proton pump inhibitors in cancer therapy. J Transl Med. 2015;13:368.
   PubMed Web of Science ®Google Scholar
• Luciani F, Spada M, Milito AD, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22):1702–1713.
   PubMed Web of Science ®Google Scholar
• Wang B-Y, Zhang J, Wang J-L, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015;34:85.
   PubMed Web of Science ®Google Scholar
• Kichenadasse G, Miners JO, Mangoni AA, et al. Proton pump inhibitors and survival in patients with colorectal cancer receiving fluoropyrimidine-based chemotherapy. J Natl Compr Canc Netw. 2021;19(9):1037–1044.
   PubMedGoogle Scholar
• Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2017;3(6):767–773.
   PubMed Web of Science ®Google Scholar
• Lowrance WT, Ordoñez J, Udaltsova N, et al. CKD and the risk of incident cancer. J Am Soc Nephrol. 2014;25(10):2327–2334.
   PubMedGoogle Scholar